FOP Clinical Trial Update

Original posting updated on Nov. 30, 2017

Two pharmaceutical companies are now recruiting for FOP clinical trials

It’s an exciting time in FOP research as not one, but two pharmaceutical companies with investigational drugs to treat FOP are now recruiting for worldwide clinical trials.*** The decision to enroll in a clinical trial is an important one, and not everyone who wants to enroll will meet the entrance criteria. Eligible individuals who do participate will be helping to speed up the drug development process and will have access to potential treatments for FOP that are not yet on the market. Patients taking part in clinical trials will also receive specialized, multi-disciplinary medical care throughout the entire clinical trial.  

Clinical trial participation is a commitment that is not to be taken lightly and there are many factors for you and your family or other caregivers to consider.
 
With two clinical trials recruiting patients, you will want to start considering whether you are eligible to participate and which trial might be right for you. Below is a quick overview of several factors that you’ll want to consider. Click the links below for more details on the trials being conducted by Clementia and Regeneron.
 

Clementia_and_Regeneron_(3).jpg

*After 6 months of a placebo control, all study participants will then receive REGN2477 for 6 months.
**Click buttons below for additional study participation criteria, or visit clinicaltrials.gov.
***A third potential treatment for FOP is in a clinical trial; but the trial is being run by Kyoto University and is only available in Japan.

The best resource for helping you to make a decision about participating in an FOP clinical trial is your physician. If you have general questions about clinical trials, you can contact Anitha Devadason, IFOPA Program Manager, at anitha.devadason@ifopa.org or (816) 854-0920.

button_clementia-move-trial.jpg

button_regeneron-lumina-trial.jpg

Make a Difference

Donate Connect Fundraise
Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter